Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC

Isabel FigueroaPreclinical Translational Pharmacokinetics DepartmentCorrespondence[email protected]

Doug LeipoldPreclinical Translational Pharmacokinetics Department

Steve LeongTranslational Oncology Department

Bing ZhengTranslational Oncology Department

Montserrat Triguero-CarrascoBioanalytical Sciences Department

Aimee Fourie-O'DonohueBiochemical and Cellular Pharmacology Department

Katherine R. KozakBiochemical and Cellular Pharmacology Department

Keyang XuBioanalytical Sciences Department

Melissa SchuttenSafety Assessment Department Genentech Inc., South San Francisco, CA, USA

Hong WangSafety Assessment Department Genentech Inc., South San Francisco, CA, USA

Andrew G. PolsonTranslational Oncology Department

Amrita V. KamathPreclinical Translational Pharmacokinetics DepartmentCorrespondence[email protected]

Your download is now in progress and you may close this window